UBS retained buy rate for CSL

CSL Limited (ASX: CSL)

A note out of UBS reveals that its analysts have retained their buy rating and $346.00 price target on this biotherapeutics giant’s shares. According to the note, the broker’s research shows that CSL has opened 21 new plasma collection centres since the start of the financial year. It believes this will help mitigate some of the plasma collection headwinds it is facing because of the pandemic. And while UBS still expects plasma collections to fall meaningfully, it remains positive on the company and appears to expect other areas of the business to pick up the slack